FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2173821673> ?p ?o ?g. }

• W2173821673 endingPage "75" @default.
• W2173821673 startingPage "75" @default.
• W2173821673 abstract "Importance Several randomized clinical trials have demonstrated the efficacy of preexposure prophylaxis (PrEP) in preventing human immunodeficiency virus (HIV) acquisition. Little is known about adherence to the regimen, sexual practices, and overall effectiveness when PrEP is implemented in clinics that treat sexually transmitted infections (STIs) and community-based clinics serving men who have sex with men (MSM). Objective To assess PrEP adherence, sexual behaviors, and the incidence of STIs and HIV infection in a cohort of MSM and transgender women initiating PrEP in the United States. Design, Setting, and Participants Demonstration project conducted from October 1, 2012, through February 10, 2015 (last date of follow-up), among 557 MSM and transgender women in 2 STI clinics in San Francisco, California, and Miami, Florida, and a community health center in Washington, DC. Data were analyzed from December 18, 2014, through August 8, 2015. Interventions A combination of daily, oral tenofovir disoproxil fumarate and emtricitabine was provided free of charge for 48 weeks. All participants received HIV testing, brief client-centered counseling, and clinical monitoring. Main Outcomes and Measures Concentrations of tenofovir diphosphate in dried blood spot samples, self-reported numbers of anal sex partners and episodes of condomless receptive anal sex, and incidence of STI and HIV acquisition. Results Overall, 557 participants initiated PrEP, and 437 of these (78.5%) were retained through 48 weeks. Based on the findings from the 294 participants who underwent measurement of tenofovir diphosphate levels, 80.0% to 85.6% had protective levels (consistent with ≥4 doses/wk) at follow-up visits. African American participants (56.8% of visits; P  = .003) and those from the Miami site (65.1% of visits; P P  = .02) and those reporting at least 2 condomless anal sex partners in the past 3 months (88.6%; P  = .01) were more likely to have protective levels. The mean number of anal sex partners declined during follow-up from 10.9 to 9.3, whereas the proportion engaging in condomless receptive anal sex remained stable at 65.5% to 65.6%. Overall STI incidence was high (90 per 100 person-years) but did not increase over time. Two individuals became HIV infected during follow-up (HIV incidence, 0.43 [95% CI, 0.05-1.54] infections per 100 person-years); both had tenofovir diphosphate levels consistent with fewer than 2 doses/wk at seroconversion. Conclusions and Relevance The incidence of HIV acquisition was extremely low despite a high incidence of STIs in a large US PrEP demonstration project. Adherence was higher among those participants who reported more risk behaviors. Interventions that address racial and geographic disparities and housing instability may increase the impact of PrEP." @default.
• W2173821673 created "2016-06-24" @default.
• W2173821673 creator A5001340992 @default.
• W2173821673 creator A5019635523 @default.
• W2173821673 creator A5023161423 @default.
• W2173821673 creator A5025642389 @default.
• W2173821673 creator A5027160485 @default.
• W2173821673 creator A5029133680 @default.
• W2173821673 creator A5029718424 @default.
• W2173821673 creator A5029871990 @default.
• W2173821673 creator A5040530822 @default.
• W2173821673 creator A5053805839 @default.
• W2173821673 creator A5054571824 @default.
• W2173821673 creator A5055249273 @default.
• W2173821673 creator A5057458575 @default.
• W2173821673 creator A5069190829 @default.
• W2173821673 creator A5069207241 @default.
• W2173821673 creator A5072985315 @default.
• W2173821673 creator A5073840195 @default.
• W2173821673 creator A5076551858 @default.
• W2173821673 creator A5077382357 @default.
• W2173821673 creator A5084238523 @default.
• W2173821673 creator A5085929556 @default.
• W2173821673 creator A5088042303 @default.
• W2173821673 creator A5088294186 @default.
• W2173821673 date "2016-01-01" @default.
• W2173821673 modified "2023-10-16" @default.
• W2173821673 title "Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services" @default.
• W2173821673 cites W1550111394 @default.
• W2173821673 cites W1966067630 @default.
• W2173821673 cites W1967136933 @default.
• W2173821673 cites W1970463247 @default.
• W2173821673 cites W1970913830 @default.
• W2173821673 cites W1975970108 @default.
• W2173821673 cites W1976513589 @default.
• W2173821673 cites W1981177608 @default.
• W2173821673 cites W1981285149 @default.
• W2173821673 cites W1983907369 @default.
• W2173821673 cites W1994202435 @default.
• W2173821673 cites W2019764023 @default.
• W2173821673 cites W2026939358 @default.
• W2173821673 cites W2029513457 @default.
• W2173821673 cites W2039503871 @default.
• W2173821673 cites W2044369525 @default.
• W2173821673 cites W2054763716 @default.
• W2173821673 cites W2070660143 @default.
• W2173821673 cites W2097401695 @default.
• W2173821673 cites W2103920597 @default.
• W2173821673 cites W2117057469 @default.
• W2173821673 cites W2135466424 @default.
• W2173821673 cites W2141151762 @default.
• W2173821673 cites W2150155590 @default.
• W2173821673 cites W2150644408 @default.
• W2173821673 cites W2151522612 @default.
• W2173821673 cites W2159585223 @default.
• W2173821673 cites W2162226934 @default.
• W2173821673 cites W2163583669 @default.
• W2173821673 cites W2163830090 @default.
• W2173821673 cites W2168251450 @default.
• W2173821673 cites W2171609071 @default.
• W2173821673 cites W2172212902 @default.
• W2173821673 cites W2312573952 @default.
• W2173821673 cites W2315459740 @default.
• W2173821673 cites W2324968015 @default.
• W2173821673 cites W2329786000 @default.
• W2173821673 cites W2335473073 @default.
• W2173821673 cites W2520530714 @default.
• W2173821673 cites W96672595 @default.
• W2173821673 doi "https://doi.org/10.1001/jamainternmed.2015.4683" @default.
• W2173821673 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5042323" @default.
• W2173821673 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26571482" @default.
• W2173821673 hasPublicationYear "2016" @default.
• W2173821673 type Work @default.
• W2173821673 sameAs 2173821673 @default.
• W2173821673 citedByCount "498" @default.
• W2173821673 countsByYear W21738216732015 @default.
• W2173821673 countsByYear W21738216732016 @default.
• W2173821673 countsByYear W21738216732017 @default.
• W2173821673 countsByYear W21738216732018 @default.
• W2173821673 countsByYear W21738216732019 @default.
• W2173821673 countsByYear W21738216732020 @default.
• W2173821673 countsByYear W21738216732021 @default.
• W2173821673 countsByYear W21738216732022 @default.
• W2173821673 countsByYear W21738216732023 @default.
• W2173821673 crossrefType "journal-article" @default.
• W2173821673 hasAuthorship W2173821673A5001340992 @default.
• W2173821673 hasAuthorship W2173821673A5019635523 @default.
• W2173821673 hasAuthorship W2173821673A5023161423 @default.
• W2173821673 hasAuthorship W2173821673A5025642389 @default.
• W2173821673 hasAuthorship W2173821673A5027160485 @default.
• W2173821673 hasAuthorship W2173821673A5029133680 @default.
• W2173821673 hasAuthorship W2173821673A5029718424 @default.
• W2173821673 hasAuthorship W2173821673A5029871990 @default.
• W2173821673 hasAuthorship W2173821673A5040530822 @default.
• W2173821673 hasAuthorship W2173821673A5053805839 @default.
• W2173821673 hasAuthorship W2173821673A5054571824 @default.
• W2173821673 hasAuthorship W2173821673A5055249273 @default.
• W2173821673 hasAuthorship W2173821673A5057458575 @default.

• next